Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man

Calman MacLennan*, Glynis Dunn, Aarnoud P. Huissoon, Dinakantha S. Kumararatne, Javier Martin, Paula O'Leary, Ronald A. Thompson, Husam Osman, Philip Wood, Philip Minor, David J. Wood, Deenan Pillay

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

119 Citations (Scopus)

Abstract

Background Individuals who chronically excrete neurovirulent poliovirus of vaccine-origin are of considerable concern to the Global Polio Eradication programme. Chronic infection with such polioviruses is a recognised complication of hypogammaglobulinaemia. Methods We did a series of in-vitro and in-vivo therapeutic studies, with a view to clearing persistent neurovirulent poliovirus infection in an individual with common variable immunodeficiency, using oral immunoglobulin, breast milk (as a source of secretory IgA), ribavirin, and the anti-picornaviral agent pleconaril. We undertook viral quantitation, antibody neutralisation and drug susceptibility assays, and viral gene sequencing. Findings Long-term asymptomatic excretion of vaccine-derived neurovirulent poliovirus 2 was identified in this hypogammaglobulinaemic man, and was estimated to have persisted for up to 22 years. Despite demonstrable in-vitro neutralising activity of immunoglobulin and breast milk, and in-vitro antiviral activity of ribavirin, no treatment was successful at clearing the virus, although in one trial breast milk significantly reduced excretion levels temporarily. During the course of study, the virus developed reduced susceptibility to pleconaril, precluding the in-vivo use of this drug. Sequence analysis revealed the emergence of a methionine to leucine mutation adjacent to the likely binding site of pleconaril in these isolates. Interpretation Chronic vaccine-associated poliovirus infection in hypogammaglobulinaemia is a difficult condition to treat. It represents a risk to the strategy to discontinue polio vaccination once global eradication has been achieved.

Original languageEnglish
Pages (from-to)1509-1513
Number of pages5
JournalThe Lancet
Volume363
Issue number9420
DOIs
Publication statusPublished - 8 May 2004

Fingerprint

Dive into the research topics of 'Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man'. Together they form a unique fingerprint.

Cite this